Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancerEmily Hinchcliff, Amir A. Jazaeri, David M. Gershenson et al.|Cancer|2023Cited by 18